WeightWatchers files for Chapter 11, cutting $1.15 billion in debt as GLP-1 drugs reshape dieting

WW International, the company that operates WeightWatchers, filed for Chapter 11 bankruptcy protection on May 6, 2025, in the U.S. Bankruptcy Court for the District of Delaware, aiming to eliminate about $1.15 billion of the roughly $1.6 billion in debt it had accumulated ^[1][3]. It was a prepackaged filing, meaning the company had negotiated terms with a group of lenders before going to court ^[3].

The confirmed plan cut the company's debt by approximately $1.15 billion, more than 70%, according to the law firm Simpson Thacher, which represented WW ^[2]. Lenders and noteholders received their pro rata share of $465 million in new senior secured term loans due 2030, plus 91% of the new common equity; existing shareholders received the remaining 9% ^[2]. The bankruptcy court approved the plan on June 17, 2025, and the company exited the court-supervised process on June 24, 2025 ^[2]. Before the filing, WW said it expected to emerge as a publicly traded company ^[5].

WW reported a net loss of $345.7 million for 2024, and its subscription revenues fell 5.6% compared with the year before ^[1]. BBC News put the annual loss at $346 million ^[5]. Full-year 2024 revenue was $786 million, more than $1 billion below the company's all-time high of $1.84 billion in 2012 ^[3]. Axios reported six straight full-year revenue declines and three straight nine-digit net losses, with losses totaling more than $700 million over the previous three years ^[3]. In its Chapter 11 petition, WW estimated assets and liabilities in the range of $1 billion to $10 billion ^[1]. BBC reported total liabilities of $1.88 billion, greater than the value of its assets ^[5]. Shares fell 40% in extended trading after the filing was announced ^[1], and were down 60% since the Wall Street Journal first reported in April that a filing was being prepared ^[1].

WeightWatchers began as a weekly weight-loss support group meeting with 400 attendees and grew into a worldwide brand ^[1][5]. It renamed itself WW International in 2018 to focus on broader wellness rather than weight loss alone ^[1], and in 2023 it acquired the telehealth provider Sequence to move into weight-loss drug prescribing ^[1][3]. For the first three months of 2025, subscription revenues fell 9.3% year over year, while revenue from its clinical business, which includes weight-loss medication, rose more than 57% ^[5]. Reuters attributed the pressure on WW's traditional programs to the rising popularity of GLP-1 drugs such as Novo Nordisk's Wegovy, a semaglutide, and Eli Lilly's Zepbound, a tirzepatide ^[1].

The company said it "remains fully operational during the reorganization process and there will be no impact to members or the plans they rely on to support their weight management goals" ^[3]. WW also said some customers would receive court notifications but should not need to take any action ^[5]. Chief executive Tara Comonte said the plans carried "the overwhelming support of our lenders" ^[5] and that "for more than 62 years, WeightWatchers has empowered millions of members to make informed, healthy choices, staying resilient as trends have come and gone" ^[3][5].

Why it matters for patients

WeightWatchers is one of the largest consumer weight-management brands in the United States, and it now sells prescription weight-loss medication through the same clinical business that grew more than 57% in the first quarter of 2025 ^[5]. That means the commercial weight-loss market is increasingly tied to GLP-1 prescribing, the class that includes semaglutide (Ozempic, Wegovy and Rybelsus) and tirzepatide (Mounjaro and Zepbound), rather than to meetings and food tracking alone ^[1][5].

For people who use WW programs or get prescriptions through its clinical arm, the company's position is that service continues without interruption ^[3]. Whether pricing, program features or clinical services change after the restructuring has not been reported. The sources also do not disclose how the new lender ownership will affect the company's direction, staffing or the terms offered to members.

The bankruptcy reflects a shift that predates this filing: demand for traditional diet programs fell as the drugs became more popular ^[1][5], and WW had already spent two years repositioning around prescribing them ^[1][3]. How well a company built on behavioral programs competes with drug-based treatment is not settled by these accounts. What is established is the financial result: a 60-year-old brand that once reached $1.84 billion in annual revenue filed for bankruptcy with liabilities exceeding its assets ^[3][5].